Category Archives: LEDs

Oct. 6, 2008 — European nanoelectronics research consortium IMEC and Japanese gases/equipment supplier Taiyo Nippon Sanso Corp. (TNSC) say they will jointly develop manufacturing technology for high-efficiency LED devices, TNSC’s first such collaboration in Europe.

Under terms of the deal, TNSC and IMEC will develop high-efficiency green LED device manufacturing technology based on IMEC’s compound semiconductors device technology, with research mainly carried out at IMEC’s facilities in Leuven, Belgium, building on previous work in strain engineering on large wafers and in-situ growth monitoring.

The goal is to tap into increasing demand for brighter green LEDs for future applications such as backlights for high-vision LCD TVs, according to the partners.

“The relationship with IMEC will enhance Taiyo Nippon Sanso’s position as a MOCVD tool maker in the LED compound semiconductor market,” said Mike Hara, senior managing director of TNSC.

October 2, 2008: Purdue U. researchers have developed a method of using nanoparticles to deliver treatments to injured brain and spinal cord cells.

A team led by Richard Borgens of the School of Veterinary Medicine’s Center for Paralysis Research and Welden School of Biomedical Engineering coated silica nanoparticles with a polymer to target and repair injured guinea pig spinal cords. That research is being published in the October edition of the journal Small.

The team used the coated nanoparticles to deliver both polymer and hydralazine to cells with secondary damage from a naturally produced toxin. That research was published in August by the journal Nanomedicine.

Borgens’ group had previously shown benefits of the polymer polyethylene glycol, or PEG, to treat rats with brain injuries and dogs with spinal cord injuries. PEG specifically targets damaged cells and seals the injured area, reducing further damage. It also helps restore cell function, Borgens said.

“These particles are so tiny they can’t be seen with a regular microscope. They are about the size of a large virus. So you can inject as many as you need,” he said, adding that “they are safe inside bodies.”

In the first study, the researchers coated the nanoparticles with PEG to treat guinea pig spinal cord injuries. The treated spinal cord cells showed improved physiological functioning.

In the second study, the researchers added both PEG and hydralazine, an antihypertension drug, to mesoporous silica nanoparticles. These nanoparticles have pores that can hold the drug, which is later delivered to the damaged cells. The hydralazine was added to fight off secondary damage to cells that occurs after the initial injury.

“When cells are injured, they produce natural toxins,” Borgens said. “Acrolein is the most poisonous of these toxins. It’s an industrial hazard for which hydralazine is an antidote.”

Borgens and his team introduced acrolein into cells and then treated the cells with different combinations of hydralazine and/or PEG delivered by the mesoporous silica nanoparticles. They found that the treatment restored disrupted cell function caused by acrolein.

The team concluded that the use of nanoparticles to deliver both PEG and hydralazine increased the effectiveness of earlier PEG-only treatment by controlling and concentrating release of the drug and the polymer, producing a dual treatment and prolonging the treatment’s duration.

The goal of Borgens’ research is to improve the quality of life of those who have suffered head or spinal cord injuries. “All ambulances should have PEG on board,” he said. “It can probably save thousands of people from more severe head and spinal damage.”

The researchers now are testing the PEG/hydralazine treatment on rats with brain injuries. By the end of the year, they hope to test the treatment on naturally injured paraplegic dogs.

Financial support for the studies came from the state of Indiana and an endowment from Mari Hulman George.

Sept. 30, 2008 – The sapphire substrate market will grow at a 21% annual clip through 2012 to top $400M, led by demand from LED makers now focused on Western markets where pricing remains stable, according to a report from Yole Développement.

Nitride LEDs have been the main driver for sapphire substrates, accounting for $100M in sales in 2007 and expected to keep growing 15% through 2012. But silicon-on-sapphire (SoS) devices, which were <$35M in 2007, should also cross the $100M threshold in 2011, the analyst firm notes. SoS "ultra-CMOS" technology is gaining momentum mainly for use in cell phones to replace switch technologies such as PiN diodes and GaAs pHEMT.

A major regional shift in the sapphire market for LEDs is occurring thanks to “huge pressure on prices in the main Asian regions,” Yole notes. A LED die-on-wafer now sells for $0.02-$0.03, and LED producers are pressing for as low at $17 for a 2-in. substrate, which is forcing some sapphire suppliers to “focus on western countries where market prices are more attractive.” Shifting to larger wafers is another trend, Yole notes — migration to 4-in. wafers is “booming” with announcements by Osram and Showa Denko among others, while Samsung is planning to shift to 6-in. nitride LED production, and Monocrystal is working on 8-in. c-plan sapphire.

Asia represents about two-thirds of total sapphire business revenues and more than 88% of sales into LEDs (more than half from Taiwan alone), Yole notes. Sapphire for SoS-based devices was originally located in Australia with Peregrine, but that firm’s move toward a more fabless operation is shifting work to Asia, specifically to Korean semiconductor fabs.

Kyocera is still the top global vendor with estimated 2007 sales of $100M for both electronics and optical materials, followed by Namiki and Rubicon. Russian firm Monocrystal’s acquisition of domestic firm Atlas will vault the company into the top 3 suppliers, while Honeywell is leaning toward a market exit by selling its Canadian plant to China’s SilianTech.

Sept. 29, 2008 – The annual fall gathering at the Woburn, MA Hilton for an industry panel discussion hosted by Wall Street watchers took a sideroad even before it started. One of the scheduled participants, CJ Muse of meltdown-in-progress Lehman Brothers, was understandably absent [edit: phrasing changed to moderate tone. –J.M.]. Another analyst, Theodore O’Neill of Kaufman Brothers, didn’t use any slides in briefly overviewing photovoltaics. What resulted was a more open discussion forum with attendees and some energetic back-and-forth about the tense relationship between the investment world and the semiconductor industry.

Panel moderator Robert Halliday, CFO of Varian Semi. Equip. Assoc., evoked three themes resonating in the sector right now: what will happen to semiconductor capital spending in 2009, and what are chipmakers doing differently now and in the future; and the shaky state of financial markets. Some big important chipmakers simply aren’t buying tools, he noted; 2008 capex is likely to be down -35% or more, and even foundries, who also shave been spending less, are said to be feeling increasingly conservative lately. Balance sheets are “ugly,” he said, showing how Taiwan DRAM firms’ opex is now a miserable -50%, and has been in the red for more than a year. Projections into 2009 are starting to erode as well, he noted, citing a quartet of financial analysts expecting flat or slightly down capex.

However, Halliday noted he’s “reasonably optimistic” bout the longer-term picture. Samsung still plans to invest in solid-state storage devices, with a late 2010 timeframe, for example.

Taiwan DRAM companies’ estimated OpEx %, showing large losses and negative cash. (Source: VSEA)

Asking attendees to not “shoot the messenger,” Needham & Co. analyst Vernon Essi noted there’s now limited capital for “cavalier” investments fueled by cheap money and high risk/reward, and consolidation has “growth-managed” companies such as Intel, TSMC, and Samsung to spend more consistently. Capital equipment buyers want more for less (an “ominous trend,” he warned), and are pursuing lower-cost infrastructure, notably in Taiwan now that trade restrictions with China are being relaxed. The good news, from a financial perspective, is that semiconductor-industry companies “are built with hard-to-find money,” he said. The bad news: that money doesn’t come easy, and there are offshore economies where it does to others.

Essi urged attendees to prepare for what will be a “downslope of ingenuity” and a new “Dark Age of innovation” in the chip industry, where exit strategies for entrepreneurship favor aggregation and the IPO climate has dried up. Not only has Moore’s Law failed, he said, but so has scaling across most technology fronts (software, comm, and hardware), and companies will be investing a lot more on trailing technologies. Safe harbors to seek in such stormy waters, Essi suggested, include power analog, multi-load ICs using SOI approaches and BCD implementation. Renewables are “the new semi drug,” he cautioned, and RF is “not fully around the innovation curve yet,” but there are future opportunities in mixed-mode functionality. He also urged chip companies to “chum up” to OEM customers for one-off R&D projects. OEM firms are one side of the vice that’s squeezing out chip firms (Asian design/dev work is the other) — Analog firms, for example (e.g., Broadcom, Marvell, TI) are being pressed by Apple and IC designers on one end, and by Mediatek and TSMC on the other. “Their margins have nowhere to go but down. There’s no backstop to it,” he said.

Q&A: Pride in the US, semi sector

Much of the morning’s discussion was in a back-and-forth with audience members about domestic policies that impact the US financial and semiconductor sectors. All three panelists agreed that there probably won’t be a new leading-edge fab in the US except maybe as a 450mm collaboration (while Asia and even Europe continue to woo more business). But there is still great opportunity in shared R&D, noted Halliday, pointing to collaborative work being done by the “increasingly powerful” IBM-led group in Albany, NY, as well as IMEC in Europe and Japan’s Selete.

Another touchy issue is intellectual property, a “myopic” area where some overseas companies (and regions) view IP differently, said Essi. This area has become important enough that many IC companies now break out litigation expenses as a line-item, he pointed out. “The deck is stacked against the US,” when an engineer in China costs one-tenth that of a US worker, he said. O’Neill added that a more worrisome problem is what’s being manufactured in the US, and Essi reiterated the Catch-22 that many US firms have already invested in overseas manufacturing and that re-imports are “huge to consumer America.” And some firms, he lamented, are taking a disturbing next step to actually list on those foreign markets. A key problem, he said, is that the lobbying for the semiconductor industry is lousy — though it should be noted that SEMI and SIA and others have been vocal about the need for friendly legislation, e.g. federal funding for sciences and R&D, and tax issues.

All three panelists agreed that China seems interested in building up a domestic chip equipment supplier base, but there seems to be no reliable timeframe. Essi projected that 2nd-tier tool vendors likely will emerge first but only if they can be sufficiently profitable. Halliday reminded the audience, though, that chipmakers still recognize value in tools that help them make chips faster and with better efficiency — but emphasized that suppliers also take on significant pressure to not undermine a $3B fab investment with a $100M tool that screws up yields.

Market maturation: Textiles to solar

A question from the audience about promising new growth markets for chip firms (and their suppliers) drew both positive and negative assessment from both the panel and other attendees. LEDs, for example, are very silicon-intensive, with “no shortage of technology behind the scenes,” noted Essi, but quickly added that Philips has been working in this area for years with little to show for commercialization. And while there would seem to be a lot of opportunities in architecture and commercial lighting for LEDs, innovation will come in vertical areas such as FPD TV backlighting to replace CCFL lamps. O’Neill noted that at $100/lamp there’s a six-year payback for LEDs vs. a 60W bulb, and that 5B light bulbs can be replaced in the US alone. An audience member suggested that in seven years the LED market could be bigger than DRAM — but another attendee replied that LED devices also depend semiconductor-supported systems (e.g. dimmers), and pointed out that LED poster-child Philips’ sales are dwarfed by Applied Materials.

And what of today’s other emerging-market darling, photovoltaics? Halliday noted similarities to the chip industry ~20 years ago (e.g., use of technologies like diffusion), but long-term efficiency is a bigger concern than cost. O’Neill, revisiting political themes, said there are no plans to put an AMAT Sunfab line in the US now, though that will change if a “credible” US energy policy is adopted (he chided that there’s a $2k cap on refunds for residential solar installations, but no cap on commercial ones).

One attendee likened the semiconductor industry’s current environment to where the textile industry was 100 years ago — a comparison met with mumbles and snickers from the audience, which knows firsthand how New England’s former mill towns are wrestling with the economic and physical burden of those aged looming brick warehouses. Instead of textiles, Essi suggested we’re in more like what the UK found itself in post-WWII, he suggested — and reminded the audience that this required 20 years of rebuilding.

Q&A: Brain drain, and keeping the faith

The issue of skilled workers also came up; several attendees noted how the semiconductor industry is “graying,” and Halliday agreed that “this is bigger than many other issues.” Will a fresh-faced EE be drawn to a first job maintaining a chipmaking tool at a customer site, or pursuing a hot high-growth field like solar that can fulfill not only monetary goals but also feed the desire to create and innovate? Essi also blamed the US for not sowing the seeds to cultivate EEs, noting that one domestic firm is actually cultivating them in Vietnam instead. And this industry that needs help in lobbying the government hasn’t helped its own cause with lousy branding and recruitment, he added, specifically slamming Intel’s amusing but inane bunny-suit ads of the 1990s.

All the negativity raised the hackles of longtime industry figure Bill Tobey, now consultant and SST Editorial Advisory Board member, who stood up and took Essi to the proverbial woodshed for being “so negative about semiconductors” though chip technologies and devices help underpin the darling emerging growth markets in solar, bio, etc. “You [meaning Wall Street] have no faith in what we can do,” he admonished, yet “you’re investing in industries that depend on what we’ve done, and are doing!” Essi accepted the criticism, but replied that despite some top-down opportunities (e.g. in solar) there simply isn’t the same promise of profitability and success as there was in analog in the 1980s. “Where is the innovation long-term?” he asked. “Solar is not the Holy Grail for you guys.”

Halliday urged attendees to evolve and above all be positive, since this industry has a higher barrier to entry than most (e.g., complex tools, service, IP). “We’re not where we were 15 years ago” with 16% CAGR, he said, but there’s still growth at a small clip — and that’s better than quite a few other struggling industries can say. — J.M.

September 24, 2008: A research team, led by investigators at the Department of Surgery at Jefferson Medical College (JMC) of Thomas Jefferson U. and the Kimmel Cancer Center at Jefferson, has achieved a substantial “kill” of pancreatic cancer cells by using nanoparticles to successfully deliver a deadly diphtheria toxin gene.

The findings, set to be published in the October issue of Cancer Biology & Therapy, reflect the first time this unique strategy has been tested in pancreatic cancer cells, and the success seen offers promise for future pre-clinical animal studies, and possibly, a new clinical approach.

The researchers found that delivery of a diphtheria toxin gene inhibited a basic function of pancreatic tumor cells by over 95%, resulting in significant cell death of pancreatic cancer cells six days after a single treatment. They also demonstrated that the treatment targets only pancreatic cancer cells and leaves normal cells alone, thus providing a potential ‘therapeutic window.’ Further, they are targeting a molecule that is found in over three-quarters of pancreatic cancer patients.

“For the pancreatic cancer world, this is very exciting,” says the study’s lead author, molecular biologist Jonathan Brody, assistant professor, Department of Surgery at JMC. “There are no effective targeted treatments for pancreatic cancer, aside from surgery for which only a minority of patients qualify. We are in great need of translating the plethora of molecular information we know about this disease to novel therapeutic ideas.”

September 24, 2008: Evident Technologies Inc. announced the issuance of US Patent No. 7,399,429 covering the ability to make semiconductor nanocrystals from III-V materials, including indium gallium phosphide.

Evident Technologies’ array of semiconductor nanocrystal materials are used in products ranging from electronics to life science reagents. The company says the new patented technology will help companies and research institutes continue the development of quantum dot applications from energy conversion, to LEDs , to life science.

“The unique spectral properties of these III-V quantum dot nanocrystals include absorption in the ultraviolet through the near-infrared range and emission in the near-infrared range, and are ideal for several applications within the life sciences,” said Todd Nelson, CEO of eBioscience, the worldwide exclusive licensee of this technology within the life sciences industry. “We believe our customers will find that the products enabled by this technology will represent a significant advancement in multicolor applications, and will allow us to develop the next generation of eFluor in-vivo imaging reagents.”

“The issuance of this key patent underscores the fact that Evident Technologies remains a pioneer in the development of novel and proprietary semiconductor nanocrystals, and affords us broad protection in a rapidly growing segment of the market,” stated Clint Ballinger, CEO of Evident Technologies.

September 18, 2008: Compugen Ltd. announced that its proprietary DAC Blockers platform has led to the discovery of CGEN-25008, a novel peptide antagonist of the Clusterin protein, and that recently analyzed in vitro and initial in vivo results from cell-based assays and a lung cancer mouse model indicate that CGEN-25008 reduces the growth rate of several cancer cell lines and significantly enhances the anti-cancer activity of Taxol, a frequently used cancer chemotherapeutic drug.

The novel peptide CGEN-25008 has been shown to slow the growth of human non-small cell lung cancer cells and other malignant cell lines including breast, prostate, colon, and melanoma cancers when tested directly on them. In addition, administration of CGEN-25008 in remarkably low doses (1 nano Molar) in combination with Taxol was shown to increase the cancer cells’ sensitivity to Taxol, allowing a ten-fold reduction in the concentration of Taxol while maintaining the same anti-cancer effect.

A combination of a higher dose of CGEN-25008 (80 nano Molar) with Taxol was shown to result in a 40%t increase over the maximal anti-cancer effect achieved by Taxol alone.

“In a mouse model of lung cancer, the tumor size decreased significantly more when Taxol was given in combination with CGEN-25008, as compared to when mice were treated with Taxol alone,” noted Yossi Cohen, VP of R&D at Compugen, in a statement. “This may ultimately translate to lower required doses of chemotherapy, with reduced side effects, while maintaining its comparable therapeutic benefits or potentially strengthening the maximal anti-cancer effects achieved.”

September 12, 2008: Scientists have developed nanometer-sized ‘cargo ships’ that can sail throughout the body via the bloodstream without immediate detection from the body’s immune radar system and ferry their cargo of anti-cancer drugs and markers into tumors that might otherwise go untreated or undetected.

In a forthcoming issue of the Germany-based chemistry journal Angewandte Chemie, scientists at the U. of California/San Diego, UC/Santa Barbara, and MIT report that their nano cargo-ship system integrates therapeutic and diagnostic functions into a single device that avoids rapid removal by the body’s natural immune system.

“The idea involves encapsulating imaging agents and drugs into a protective ‘mother ship’ that evades the natural processes that normally would remove these payloads if they were unprotected,” said Michael Sailor, a professor of chemistry and biochemistry at UCSD who headed the team of chemists, biologists and engineers that turned the fanciful concept into reality.

These “mother ships,” 50nm in diameter, are equipped with an array of molecules on the surface that help target and penetrate tumor cells in the body. Sailor thinks they eventually could be the key to more effectively deliver toxic anti-cancer drugs to tumors in high concentrations without harming other parts of the body.

The researchers loaded their ships with three payloads before injecting them in the mice. Two types of nanoparticles, superparamagnetic iron oxide and fluorescent quantum dots, were placed in the ship’s cargo hold, along with the anti-cancer drug doxorubicin. The iron oxide nanoparticles allow the ships to show up in a magnetic resonance imaging (MRI) scan, while the quantum dots can be seen with a fluorescence scanner which provides higher resolution.


UCSD graduate student Ji-Ho Park holds a vial containing the nanometer-sized cargo ships, composed of a magnetic nanoparticle, a fluorescent quantum dot and an anti-cancer drug molecule that will be left on the site of the tumor. (Source: Luo Gu, UCSD)

“One can imagine a surgeon identifying the specific location of a tumor in the body before surgery with an MRI scan, then using fluorescence imaging to find and remove all parts of the tumor during the operation,” said Sailor, in a statement.

The team found to its surprise in its experiments that a single mother-ship can carry multiple iron oxide nanoparticles, which increases their brightness in the MRI image. “The ability of these nanostructures to carry more than one superparamagnetic nanoparticle makes them easier to see by MRI, which should translate to earlier detection of smaller tumors,” he said. “The fact that the ships can carry very dissimilar payloads — a magnetic nanoparticle, a fluorescent quantum dot, and a small molecule drug — was a real surprise.”


A vial of anti-cancer nano ships glows red under a black light. The particles glow red because they contain fluorescent “quantum dot” nanoparticles. (Source: Luo Gu, UCSD)

Sept. 12, 2008: Evident Technologies Inc. announced the commercial availability of its evidot LED products based on semiconductor nanocrystal technology. Whereas traditional LEDs are available in a limited set of standard colors (blue, green, red, etc.), Evident’s new products enables LEDs to emit any color, including high-quality white light.

“This nanotechnology breakthrough enables us to make LEDs of any color without requiring complex electronic controls, liberating the end-user or designer to dream up many new applications,” stated Clint Ballinger, CEO of Evident Technologies. “The limitations of designing a product around the existing, traditional colored LED are removed.”

Applications that could utilize this new product line include signage to make specific brand colors, LCD backlights to increase display color ranges, and high color rendered white LEDs in a wide range of color temperatures. The new products are available in lamp-type or surface mounted LED packages.

“As the world becomes increasingly mindful of the need to conserve energy, LED use has grown tremendously,” said Dave Duncan, COO Evident Technologies. “Now we are bringing new colors to these efficient light sources.”

Sept. 8, 2008 – New government mandates will help nearly double the global shipments of automotive microelectromechanical systems (MEMS) from 2006-2012 (a 12% CAGR), while sales surge to $2.1B (8% CAGR), according to data from iSuppli.

The automotive MEMS sensor segment consists of 26 applications spanning the chassis, power train, and body electronics, incorporating devices such as inertial sensors, pressure sensors, flow sensors, infrared sensors, and emerging sensors. These devices perform various safety, control, and environmental functions ranging from airbag collision detection to tire pressure monitoring to engine management.

In the US and Europe, chassis safety-related mandates require implementing electronic stability control (ESC) systems and tire-pressure monitors, which is driving rapid growth in the automotive MEMS sensor market, points out Richard Dixon, senior analyst for MEMS at iSuppli, in a statement. “Both applications significantly contribute to saving lives on the roads, and tire-pressure monitors also lower fuel consumption.”

Unit shipments for various MEMS sensors are expected to surge over the 2006-2012 forecast period: MEMS pressure sensors used in tire pressure monitoring systems (TPMS) more than quadrupling (~315%) to 179M units, MEMS inertial pressure in ESC systems to 158M units (17% CAGR). In fact, these applications will push automotive MEMS sensors to outgrow the overall automotive/car electronics segments, Dixon noted.

Automotive MEMS shipments by device type


(Source: iSuppli Corp.)

While the US has led the way in implementing TPMS and ESC systems, “sweeping proposals” have been popping up in Europe too, he noted, which is good news for suppliers. “Mandates support systems that require several MEMS sensors — four TPMS pressure sensors per car, a gyroscope with one of two low-g accelerometers in a cluster, and one or more brake pressure sensor per ESC system on average,” he said. “For accelerometers and gyroscopes, mandates will more than double the number of sensors required.”

Another market driver in Europe is coming in 2009 with new stricter emission-control regulations, which will boost demand for powertrain pressure sensors used for optimizing engine operation and reducing particle emissions in diesels, Dixon noted. Other healthy MEMS markets include high-g accelerometers for airbags.

“Mandates are reshaping the supply chain,” added Jérémie Bouchaud, principal analyst for MEMS at iSuppli. For ESC systems, “transitioning rapidly from an expensive option to a standard function in just a few years will create a space for newcomers and threaten established second-tier suppliers.” Also, government mandates will likely create a market for commoditization and thus increased competition and price erosion for MEMS sensors, since all suppliers must conform to the same specs and in a range that spans the least and most expensive vehicles available.